The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Barinthus Biotherapeutics's current ratio for the quarter that ended in Mar. 2026 was 6.05.
Barinthus Biotherapeutics has a current ratio of 6.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Barinthus Biotherapeutics's Current Ratio or its related term are showing as below:
STU:2AB'
s Current Ratio Range Over the Past 10 Years
Min: 2.82 Med: 11.15 Max: 38.6
Current: 6.05
During the past 7 years, Barinthus Biotherapeutics's highest Current Ratio was 38.60. The lowest was 2.82. And the median was 11.15.
STU:2AB's Current Ratio is ranked better than 63.67% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs STU:2AB: 6.05
Barinthus Biotherapeutics (STU:2AB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Barinthus Biotherapeutics Current Ratio Related Terms
Barinthus Biotherapeutics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Current Ratio Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Current Ratio of 6.05 as of Mar. 2026. This is 46% below median its historical median of 11.15. Over the past decade, Barinthus Biotherapeutics' Current Ratio has ranged from 2.82 to 38.60. According to the industry distribution chart, Barinthus Biotherapeutics ranks #513 out of 1412 companies in the Biotechnology industry, placing it in the top 36.3%.
Is Barinthus Biotherapeutics' Current Ratio too high?
Barinthus Biotherapeutics' current Current Ratio of 6.05 is 46% below median its 10-year median of 11.15. Over the past 10 years, this metric has ranged from a low of 2.82 to a high of 38.60. The Biotechnology industry median Current Ratio is 3.90. Barinthus Biotherapeutics' value of 6.05 is 55.1% above this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #513 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Current Ratio compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #513 out of 1412 companies for Current Ratio. This puts Barinthus Biotherapeutics in the upper half of its industry. The industry median Current Ratio is 3.90. Barinthus Biotherapeutics' value of 6.05 is 55.1% above this benchmark. Historically, Barinthus Biotherapeutics' own Current Ratio has ranged from 2.82 to 38.60 over the past decade. While the company's 10-year median is 11.15 vs. the industry median of 3.90, Barinthus Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current Current Ratio of 6.05 is 55.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Current Ratio is 6.05, which is 46% below median its own 10-year median of 11.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Current Ratio of 6.05. The stock's GF Value™ is €0.94, compared to a current price of €0.57 — trading 39.9% below its estimated fair value. The current Current Ratio is 6.05, which is 46% below median its 10-year median of 11.15 and 55.1% above the Biotechnology industry median of 3.90. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Current Ratio is 6.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.57 is trading 39.9% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
Current Ratio: 6.05 (46% below median its 10-year median of 11.15)
GF Value™: €0.94 vs. price of €0.57 (39.9% below fair value)
Industry Position: 55.1% above the Biotechnology median (#513 of 1412)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
